Tissue Regenix, founded in 2006 as a spin out of Leeds University in the UK, was established to commercialize academic research in regenerative medicine. Utilizing its unique dCell technology the Company develops and commercializes biocompatible acellular scaffolds derived from xenogenic and allogenic sources for wound care, orthopedic surgery and cardiovascular applications.